The Food and Drug Administration (FDA) is seeking to block an ad touting the safety of the cholesterol drug Crestor, calling the claims misleading. The agency asked the drug's...
WASHINGTON — The Food and Drug Administration (FDA) is seeking to block an ad touting the safety of the cholesterol drug Crestor, calling the claims misleading. The agency asked the drug’s maker, AstraZeneca, to “immediately cease the dissemination” of the ad.
“The ‘patient safety’ print ad makes false or misleading safety claims that minimize the risks associated with Crestor, thereby suggesting that Crestor is safer than has been demonstrated by substantial evidence or substantial clinical experience,” the FDA said in a letter dated Tuesday.
Most Read Stories
- Mexico City is a parched and sinking capital
- Students frustrated trying to get into UW’s strict engineering program
- Officials say damage to sewage plant in Discovery Park is catastrophic
- Trump motorcade hit by 2x4, 5 students face charges
- T-Mobile one-ups Verizon’s new unlimited data plan; 4Q results top forecasts
AstraZeneca spokeswoman Emily Denney said the ad was intended only to run for a short time and that the FDA has been advised that it is no longer being used.
The advertisement in question appeared in The Washington Post on Nov. 23, prompting Dr. Sidney Wolfe of the consumer group Public Citizen to complain to the FDA. Wolfe has sought to have Crestor withdrawn from the market because of its rate of liver problems.
Crestor is one of a group of medications called statins that are used to lower cholesterol. Crestor’s prescribing information includes warnings about side effects including possible liver damage or failure.
In its complaint, the FDA took issue with the ad’s claims that FDA scientists have confirmed that concerns about the safety of the drug have no basis. It has published no such statement, the FDA said.
In addition, the FDA said, “recent public statements made by the agency contradict that conclusion.”
The FDA letter noted a recent statement by Dr. Steven Galson, its acting director for drug evaluation and research, that the agency “has been very concerned about Crestor since the day it was approved, and we’ve been watching it very carefully.”